Dosing of first patient initiates Phase 1 clinical evaluation of BMS-986506 for the treatment of advanced clear cell renal cell carcinoma, the most common form of kidney cancer Transformative moment ...
Innovative Agents Highlight Growth of Targeted Protein Degradation Platform and BMS' Leadership in Innovative Cancer Therapies The latest data presented for the three lead CELMoD agents and BCL6 LDD ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results